Open Access
Subscription Access
Exploring the Role of Antihistamines in Dermatology: A Comprehensive Overview
Abstract
Anti-histamines, originally developed to alleviate symptoms of allergies, play an important role in the field of dermatology. These drugs, which primarily target histamine receptors, participate on in a multifaceted role in managing different types of skin conditions. Histamine plays an important role in allergic reactions and inflammatory responses. In dermatology, conditions namely allergic contact dermatitis, pruritus and urticaria are manifested by an overactive histaminergic response. Anti-histamine performs by blocking histamine receptors, thereby mitigating symptoms associated with these skin disorders. Early Anti histamines, termed as first_ generated anti histamines, include drugs namely chlophenaramine and diphenhydramine. While effective in relieving itching and redness, these medications are related to the sedation because of their capability to cross blood_ brain barrier. Consequently, their use in dermatology may be restricted, particularly in cases where alertness is required. Second_ Generation Anti histamines (Modern histamines), classified as second_ Generation, exhibit an enhanced selectivity particularly for peripheral histamine receptors, minimizing central nervous system side effects. Examples include cetrizine, fexofenadine and loratidine. These drugs are essential for dermatological settings because of their efficacy in managing pruritus without causing significant sedation. Anti-histamines find application particularly in different dermatologic situations, including. Urticaria, Pruritus, Allergic Contact Dermatitis and Atopi Dermatitis. Sometimes, the combination of anti-histamines with other medications shows beneficial effect. For example, anti-histamines are frequently used I. Combination with topical corticosteroids to address both inflammatory and pruritus components of skin disorders. Finally it is concluded that anti histamines play an important role in the dermatologist’s toolkit, providing relief from symptoms associated with histamine_ mediated skin disorders.
References
Devillier, P., Roche, N., & Faisy, C. (2008). Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clinical pharmacokinetics, 47, 217-230.
Randall, K. L., & Hawkins, C. A. (2018). Antihistamines and allergy. Australian prescriber, 41(2), 41.
Cauwenberge, V., Juniper, & Star Study Investigating Group. (2000). Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clinical & Experimental Allergy, 30(6), 891-899.
Ansotegui, I. J., Bernstein, J. A., Canonica, G. W., Gonzalez-Diaz, S. N., Martin, B. L., Morais-Almeida, M., ... & Sanchez Borges, M. (2022). Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride. Allergy, Asthma & Clinical Immunology, 18(1), 41.
Iijima, S., Kojo, K., Takayama, N., Hiragun, M., Kan, T., & Hide, M. (2017). Case of cholinergic urticaria accompanied by anaphylaxis. The Journal of Dermatology, 44(11), 1291-1294.
Mahatme, M. S., Dakhale, G. N., Tadke, K., Hiware, S. K., Dudhgaonkar, S. D., & Wankhede, S. (2016). Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial. Indian journal of pharmacology, 48(6), 649.
Kawauchi, H., Yanai, K., Wang, D. Y., Itahashi, K., & Okubo, K. (2019). Antihistamines for allergic rhinitis treatment from the viewpoint of nonsedative properties. International journal of molecular sciences, 20(1), 213.
Orzechowski, R. F., Currie, D. S., & Valancius, C. A. (2005). Comparative anticholinergic activities of 10 histamine H1 receptor antagonists in two functional models. European journal of pharmacology, 506(3), 257-264.
Canonica, G. W., & Blaiss, M. (2011). Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. World Allergy Organization Journal, 4, 47-53.
Meltzer, E. O., Rosario, N. A., Van Bever, H., & Lucio, L. (2021). Fexofenadine: review of safety, efficacy and unmet needs in children with allergic rhinitis. Allergy, Asthma & Clinical Immunology, 17, 1-11.
Meltzer, E. O., Rosario, N. A., Van Bever, H., & Lucio, L. (2021). Fexofenadine: review of safety, efficacy and unmet needs in children with allergic rhinitis. Allergy, Asthma & Clinical Immunology, 17, 1-11.
Simpson, K., & Jarvis, B. (2000). Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs, 59, 301-321.
Cole, S., Bagal, S., El-Kattan, A., Fenner, K., Hay, T., Kempshall, S., ... & Speed, W. (2012). Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration. Xenobiotica, 42(1), 11-27.
Akamine, Y., & Miura, M. (2018). An update on the clinical pharmacokinetics of fexofenadine enantiomers. Expert Opinion on Drug Metabolism & Toxicology, 14(4), 429-434.
Martinez, J. M., Khier, S., Morita, S., Rauch, C., & Fabre, D. (2014). Population pharmacokinetic analysis of fexofenadine in Japanese pediatric patients. Journal of pharmacokinetics and pharmacodynamics, 41, 187-195.
Meltzer, E. O., Scheinmann, P., Rosado Pinto, J. E., Bachert, C., Hedlin, G., Wahn, U., ... & Ruuth, E. (2004). Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis–a pooled analysis of three studies. Pediatric allergy and immunology, 15(3), 253-260.
Bernstein, J. A., Lang, D. M., Khan, D. A., Craig, T., Dreyfus, D., Hsieh, F., ... & Wallace, D. (2014). The diagnosis and management of acute and chronic urticaria: 2014 update. Journal of Allergy and Clinical Immunology, 133(5), 1270-1277.
Nolin, T. D., Frye, R. F., Le, P., Sadr, H., Naud, J., Leblond, F. A., ... & Himmelfarb, J. (2009). ESRD impairs nonrenal clearance of fexofenadine but not midazolam. Journal of the American Society of Nephrology: JASN, 20(10), 2269.
Murase, J. E., Heller, M. M., & Butler, D. C. (2014). Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. Journal of the American Academy of Dermatology, 70(3), 401-e1.
Andersson, N. W., Torp-Pedersen, C., & Andersen, J. T. (2020). Association between fexofenadine use during pregnancy and fetal outcomes. JAMA pediatrics, 174(8), e201316-e201316.
Kar, S., Krishnan, A., K, P., & Mohankar, A. (2012). A review of antihistamines used during pregnancy. Journal of Pharmacology and Pharmacotherapeutics, 3(2), 105-108.
Powell, R., Leech, S. C., Till, S., Huber, P. A. J., Nasser, S. M., & Clark, A. T. (2015). BSACI guideline for the management of chronic urticaria and angioedema.
Andersson, N. W., Poulsen, H. E., & Andersen, J. T. (2020). Desloratadine use during pregnancy and risk of adverse fetal outcomes: a nationwide cohort study. The Journal of Allergy and Clinical Immunology: In Practice, 8(5), 1598-1605.
Levonorgestrel, I. (2019). Drugs and Lactation Database (LactMed)[Internet]. Bethesda (MD): National Library of Medicine (US), 63-7.
Butler, D. C., Heller, M. M., & Murase, J. E. (2014). Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. Journal of the American Academy of Dermatology, 70(3), 417-e1.
Compalati, E., Baena-Cagnani, R., Penagos, M., Badellino, H., Braido, F., Gómez, R. M., ... & Baena-Cagnani, C. E. (2011). Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. International archives of allergy and immunology, 156(1), 1-15.
Mancano, M. A. (2018). ISMP Adverse Drug Reactions: Propofol-Related Infusion Syndrome (PRIS) 1, 2; Ivermectin-Induced Stevens-Johnson Syndrome; Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis From Fexofenadine; Memantine-Related Drug Eruption. Hospital Pharmacy, 53(4), 220-222.
Bailey, D. G. (2010). Fruit juice inhibition of uptake transport: a new type of food–drug interaction. British journal of clinical pharmacology, 70(5), 645-655.
Misaka, S., Ono, Y., Taudte, R. V., Hoier, E., Ogata, H., Ono, T., ... & Shimomura, K. (2022). Exposure of fexofenadine, but not pseudoephedrine, is markedly decreased by green tea extract in healthy volunteers. Clinical Pharmacology & Therapeutics, 112(3), 627-634.
Di Mizio, G., Marcianò, G., Palleria, C., Muraca, L., Rania, V., Roberti, R., ... & Gallelli, L. (2021). Drug–drug interactions in vestibular diseases, clinical problems, and medico-legal implications. International Journal of Environmental Research and Public Health, 18(24), 12936.
Sarfraz, N., Okuampa, D., Hansen, H., Alvarez, M., Cornett, E. M., Kakazu, J., ... & Kaye, A. D. (2022). pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Health Psychology Research, 10(3).
Duran, I., Carles, J., Bulat, I., Hellemans, P., Mitselos, A., Ward, P., ... & Chien, C. (2020). Pharmacokinetic drug–drug interaction of apalutamide, part 1: clinical studies in healthy men and patients with castration-resistant prostate cancer. Clinical pharmacokinetics, 59, 1135-1148.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jan 16, 2017. Fexofenadine.
Paśko, P., Rodacki, T., Domagała-Rodacka, R., Palimonka, K., Marcinkowska, M., & Owczarek, D. (2017). Second generation H1-antihistamines interaction with food and alcohol—a systematic review. Biomedicine & Pharmacotherapy, 93, 27-39.
Gonzalez-Estrada, A., & Geraci, S. A. (2016). Allergy medications during pregnancy. The American journal of the medical sciences, 352(3), 326-331.
Van Wegberg, A. M. J., MacDonald, A., Ahring, K., Bélanger-Quintana, A., Blau, N., Bosch, A. M., ... & Van Spronsen, F. J. (2017). The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet journal of rare diseases, 12(1), 1-56.
Van Wegberg, A. M. J., MacDonald, A., Ahring, K., Bélanger-Quintana, A., Blau, N., Bosch, A. M., ... & Van Spronsen, F. J. (2017). The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet journal of rare diseases, 12(1), 1-56.
Thi, H. T., Thi, L. P., Van, T. N., Minh, P. P. T., Trong, H. N., Van, T. C., ... & Lotti, T. (2019). The Efficacy of a Two-Fold Increase of H1-Antihistamine in the Treatment of Chronic Urticaria-the Vietnamese Experience. Open Access Macedonian Journal of Medical Sciences, 7(2), 259.
Thi, H. T., Thi, L. P., Van, T. N., Minh, P. P. T., Trong, H. N., Van, T. C., ... & Lotti, T. (2019). The Efficacy of a Two-Fold Increase of H1-Antihistamine in the Treatment of Chronic Urticaria-the Vietnamese Experience. Open Access Macedonian Journal of Medical Sciences, 7(2), 259.
Paakkari, I. (2002). Cardiotoxicity of new antihistamines and cisapride. Toxicology letters, 127(1-3), 279-284.
Greenwald, P. W., Farmer, B. M., O'Neill, M., Essner, R. A., & Flomenbaum, N. E. (2016). Increasing frequency and fatality of poison control center reported exposures involving medication and multiple substances: data from reports of the American Association of Poison Control Centers 1984–2013. Clinical toxicology, 54(7), 590-596.
Skypala, I. J., De Jong, N. W., Angier, E., Gardner, J., Kull, I., Ryan, D., ... & Grimshaw, K. (2018). Promoting and achieving excellence in the delivery of Integrated Allergy Care: the European Academy of Allergy & Clinical Immunology competencies for allied health professionals working in allergy. Clinical and translational allergy, 8(1), 1-6.
Refbacks
- There are currently no refbacks.